Julian Theuriet

Julian Theuriet

Auto-generated profile, based on publicly available information

Julian Theuriet

Service d'ENMG et de pathologies neuromusculaires, centre de référence des maladies neuromusculaires PACA‐Réunion‐Rhône‐Alpes Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Groupement Est Bron France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Revue Neurologique
Verified
Journal Article
Closed access
JTJ. Theuriet
J. Theuriet
CRC. Richard
C. Richard
JBJ. Becker
J. Becker
APA. Pegat
A. Pegat
EBE. Bernard
E. Bernard
SVS. Vukusic
S. Vukusic

19 June 2023 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
JTJulian Theuriet
Julian Theuriet
GFGorka Fernandez-Eulate
Gorka Fernandez-Eulate
PLPhilippe Latour
Philippe Latour
TSTanya Stojkovic
Tanya Stojkovic
MMMarion Masingue
Marion Masingue
APAntoine Pegat
Antoine Pegat
Proximal spinal muscular atrophy (SMA) is defined by a degeneration of the anterior horn cells resulting in muscle weakness predominantly in the proximal lower limbs. While most patients carry a biallelic deletion in the SMN1 gene (localized in chromosome 5q), little is known regarding patients without SMN1-mutation, and a genetic diagnosis is not always possible. Here, we report a cohort of 24 French patients with non-5q proximal SMA from five neuromuscular centers who all, except two, had next-generation sequencing (NGS) gene panel, followed by whole exome sequencing (WES) if gene panel showed a negative result. The two remaining patients benefited directly from WES or whole genome sequencing (WGS). A total of ten patients with causative variants were identified, nine of whom were index cases (9/23 families = 39%). Eight variants were identified by gene panel: five variants in DYNC1H1, and three in BICD2. Compound heterozygous causative variants in ASAH1 were identified directly by WES, and one variant in DYNC1H1 was identified directly by WGS. No causative variant was found using WES in patients with a previous panel with negative results (14 cases). We thus recommend using primarily NGS panels in patients with non-5q-SMA and using WES, especially when several members of the same family are affected and/or when trio analyses are possible, or WGS as second-line testing if available.

27 June 2025 in European Journal of Neurology
Verified
Journal Article
Open access
JTJulian Theuriet
Julian Theuriet
LPLukas Paulet
Lukas Paulet
BABlandine Acket
Blandine Acket
FOFabienne Ory‐Magne
Fabienne Ory‐Magne
HBHocine Belbachir
Hocine Belbachir
APAntoine Pegat
Antoine Pegat
Background: This study aimed to investigate the prevalence, characteristics, and determinants of peripheral neuropathy in a large cohort of patients affected by spinocerebellar ataxia type 27B (SCA27B), a late‐onset cerebellar ataxia caused by heterozygous GAA repeat expansions in the first intron of the FGF14 gene.Methods: A retrospective, multicenter study in which medical records of SCA27B patients diagnosed between January 2023 and July 2024 in 21 French ataxia/neurogenetic centers were reviewed. Those who had undergone electrodiagnostic study were included.Results: Among 332 SCA27B patients, 170 had undergone an electrodiagnostic study and were included. Forty‐two (25%) were diagnosed with neuropathy: 16 with length‐dependent axonal sensorimotor neuropathy, 24 with length‐dependent axonal sensory neuropathy, one with sensory, and one with motor neuronopathy. Neuropathy was associated with male sex, older age at electrodiagnostic study, and risk factors for neuropathy but not with GAA expansion sizes. Patients with neuropathy had more severe disability at the last visit (median SARA score 12 vs. 8, p = 0.0024).Conclusions: The prevalence of neuropathy in SCA27B patients was similar to that reported in the elderly general population. Neuropathies were predominantly non‐specific length‐dependent axonal neuropathies, primarily driven by aging and known risk factors rather than the underlying genetic abnormality.

25 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
JTJulian Theuriet
Julian Theuriet
APAntoine Pegat
Antoine Pegat
Pascal LeblancPascal Leblanc
Pascal Leblanc
SVSandra Vukusic
Sandra Vukusic
CCCécile Cazeneuve
Cécile Cazeneuve
EBEmilien Bernard
Emilien Bernard
Biallelic mutations in the CYP7B1 gene lead to spastic paraplegia-5 (SPG5). We report herein the case of a patient whose clinical symptoms began with progressive lower limb spasticity during childhood, and who secondly developed amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) at the age of 67 years. Hereditary spastic paraplegia (HSP) gene analysis identified the compound heterozygous mutations c.825T>A (pTyr275*) and c.1193C>T (pPro398Leu) in CYP7B1 gene. No other pathogenic variant in frequent ALS/FTD causative genes was found. The CYP7B1 gene seems, therefore, to be the third gene associated with the phenoconversion from HSP to ALS, after the recently described UBQLN2 and ERLIN2 genes. We therefore expand the phenotype associated with CYP7B1 biallelic mutations and make an assumption about a link between cholesterol dyshomeostasis and ALS/FTD.

29 November 2022 in Genes
Verified
Journal Article
Open access
PDF file
APAntoine Pegat
Antoine Pegat
NSNathalie Streichenberger
Nathalie Streichenberger
NLNicolas Lacoste
Nicolas Lacoste
MHMarc R. Hermier
Marc R. Hermier
RMRita Menassa
Rita Menassa
AJarnaud jacquier
arnaud jacquier
X-linked Myopathy with Excessive Autophagy (XMEA) is a rare autophagic vacuolar myopathy caused by mutations in the Vacuolar ATPase assembly factor VMA21 gene; onset usually occurs during childhood and rarely occurs during adulthood. We described a 22-year-old patient with XMEA, whose onset was declared at 11 through gait disorder. He had severe four-limb proximal weakness and amyotrophy, and his proximal muscle MRC score was between 2 and 3/5 in four limbs; creatine kinase levels were elevated (1385 IU/L), and electroneuromyography and muscle MRI were suggestive of myopathy. Muscle biopsy showed abnormalities typical of autophagic vacuolar myopathy. We detected a hemizygous, unreported, intronic, single-nucleotide substitution c.164-20T>A (NM_001017980.4) in intron 2 of the VMA21 gene. Fibroblasts derived from this patient displayed a reduced level of VMA21 transcripts (at 40% of normal) and protein, suggesting a pathogenicity related to an alteration of the splicing efficiency associated with an intron retention. This patient with XMEA displayed a severe phenotype (rapid weakness of upper and lower limbs) due to a new intronic variant of VMA21, related to an alteration in the splicing efficiency associated with intron retention, suggesting that phenotype severity is closely related to the residual expression of the VMA21 protein.

27 June 2025 in European Journal of Human Genetics
Verified
Journal Article
Closed access
FFFanny Fontaine
Fanny Fontaine
ALAudrey Labalme
Audrey Labalme
CLChloé Laurencin
Chloé Laurencin
JTJulian Theuriet
Julian Theuriet
AJarnaud jacquier
arnaud jacquier
SAStéphane Allouche
Stéphane Allouche